INVA vs JAZZ: fair value comparison
Innoviva, Inc. and Jazz Pharmaceuticals plc · Updated 2026-10-19
INVA currently screens as undervalued while JAZZ screens as fairly valued. Within Healthcare, INVA currently sits closer to the top of our ranking by discount to fair value. INVA carries the stronger quality grade.
| INVA | JAZZ | |
|---|---|---|
| Verdict | Undervalued | Fairly valued |
| Last price | $20.78 | $210.23 |
| 12-month range | $17.57–$24.24 | $131.16–$261.62 |
| Rank by discount to fair value | #43 of 108 Healthcare | #45 of 108 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: INVA fair value analysis · JAZZ fair value analysis